首页(Home)
品牌专区(Brands-parters)
//自动完成提示
function beginSearch() {
if (document.getElementById("Keyword").value.replace(/(^\s*)|(\s*$)/g, "").length > 2) {
$("#divMsg").html("");
var tbSearch = document.getElementById("Keyword").value;
var div_msg = document.getElementById("divMsg");
div_msg.style.display = "block";
$.ajax({
type: "post",
dataType: "json", //数据格式:JSON
url: "/tools/submit_ajax.ashx?action=zhitishi",
data: { father: tbSearch },
async: false,
success: function (data) {
var str = "";
var str1 = "";
var str2 = "";
var str3 = "";
var SupplyType = data.SupplyType; //供应品类列表
var Brands = data.Brands; //品牌列表
var ProductStyle = data.ProductStyle; //产品列表
var str0 = "";
if (SupplyType != null && SupplyType != "") {
str0 += " 华海药业 Huahai Pharmaceuticals www.huahaipharm.com Huahai Pharmaceuticals, a large scaled modern pharmaceutical group that integrates fomulations, APIs(Active Pharmaceutical Ingredients) and intermediates, is developing both domestic and international markets, and performing parallel development of science, industry and commerce. With a total asset of 1,900 million yuan, the company has 11branches (subsidiaries) in the United States, Shanghai, Hangzhou, and Linhai. It occupies an area of 800,000 square meters, and has a staff of 3400. The company is entitled as National Key Hi-tech Enterprise,National Pilot Enterprise of Innovation, and China's top 500 private enterprises, and possesses a "State Certified Enterprise Technology Center". Huahai Pharmaceuticals is the largest supplier of pril products worldwide, with the annual production capacities of its dominating products "captopril" and "enalapril" both ranking first in the world. It is also the only manufacturer in the world that can realize commercial production of captopril, enalapril and lisinopril at the same time, enjoying the reputation of a "Pril Specialist". The pril drugs of the company boast absolute advantages in international markets in terms of production scale, product quality, technological skills and R&D. The company's workshops of formulation are designed in strict compliance with the international cGMP standard, where the most advanced automatic pharmaceutical production equipment in the world was introduced. We are the first pharmaceutical company in China that has passed USA FDA approval.供应分类";
$.each(SupplyType, function () {//遍历Specification
str0 += "";
});
}
if (ProductStyle != null && ProductStyle != "") {
str1 += "产品分类";
$.each(ProductStyle, function () {//遍历ProductType
str1 += "";
});
}
if (Brands != null && Brands != "") {
str2 = "品牌";
$.each(Brands, function () {//遍历Brands
str2 += "";
});
}
str = str0 + str2 + "";
$("#divMsg").html(str);
}
});
}
else if (document.getElementById("Keyword").value.replace(/(^\s*)|(\s*$)/g, "").length == 0) {
var div_msg = document.getElementById("divMsg");
div_msg.style.display = "none";
div_msg.innerHTML = "";
}
}
浙江华海药业股份有限公司创立于1989年，是一家集医药制剂和原料药为一体的制药企业，2003年在上交所上市。目前，公司注册资本5.4亿元，总资产24.7亿元，占地面积120多万平方米，并在美国、上海、江苏、杭州等地设有11家分(子)公司，共有员工3800多人。
公司是国家重点高新技术企业，国家创新型企业，浙江省医药工业十强企业，中国民营500强企业，“十一五”期间中国医药行业国际化先导企业，设有“国家级企业技术中心”、“博士后科研工作站”，是中国首家荣获“国家环境友好企业”称号的医药企业。
华海药业在国内首家制剂通过美国FDA认证，并自主拥有ANDA制剂文号，是目前国内通过美国FDA、欧洲COS、澳大利亚TGA等国际主流市场官方认证最多的制药企业之一，在制剂出口以及国际化发展领域走在了国内医药行业的前列，是目前中国唯一一家能够进行大规模、商业化制剂生产及出口欧美市场的制药企业。
公司是国内特色原料药行业的龙头企业，特别是心血管普利类、沙坦类药物领域，公司拥有核心技术，目前在国际上生产品种最多，技术水平领先，是全球最大的普利类和沙坦类药物供应商。
2011年度，公司实现销售收入约18.3亿元，比去年同期增长78.7％，实现利税约3.8亿元，比去年同期增长70％。
浙江华海药业股份有限公司
联系地址：中国浙江临海市汛桥
联系电话：0576-85010288
传真号码：0576-85016013
邮政编码：317024
E-mail：postmaster@huahaipharm.com
原料药、中间体产品销售：
电话：0576-85991124 85016086
传真：0576-85991062
E-mail：apis@huahaipharm.com
制剂销售公司：
地址：杭州市中河路258号瑞丰国际商务大厦26楼
邮政编码：310003
代理咨询：精神类产品：0571-87233658/688/3666；
心血管类产品：0571-87233626/3700/3666；
临床问题咨询：0571-87233609/3610/3703/3611
传真号码：0571-87233668
E-mail:hhsales@huahaipharm.com
上海营销公司：
地址：上海市北京东路668号科技京城东楼15层C室
邮政编码：200001
电话号码：021-53086380/81 53086386
传真号码：021-53086382
E-mail：cai@huahaipharm.com
Zhejiang Huahai Pharmaceuticals Co., Ltd.was initially founded in 1989, and the company's stock was successfully listed in Shanghai Stock Exchange in March, 2003.
